Cyclica is a leading biotechnology company specializing in applying artificial intelligence (AI) and computational biophysics to drug discovery. The company’s unique approach to drug development involves analyzing the entire proteome – the complete set of proteins in an organism – to identify potential drug targets and predict the efficacy and safety of drug candidates. Cyclica’s technology has the potential to revolutionize the drug discovery process by providing a more efficient and cost-effective method for identifying and developing new drugs.

The company was founded in 2013 in Toronto, Canada, by a team of experienced scientists and entrepreneurs with a shared vision of using AI to accelerate drug discovery. Cyclica’s mission is to improve global health by developing safer and more effective drugs in a timely and cost-effective manner. The company has received significant funding from venture capital firms, including GreenSky Capital and Epic Capital, as well as research grants from the Canadian government.

Cyclica’s approach to drug discovery is based on its proprietary technology platform, Ligand Express, which uses AI and computational biophysics to analyze the proteome and predict the interactions between potential drug candidates and protein targets. Ligand Express incorporates several AI and machine learning algorithms, including deep learning, to analyze large datasets of protein-ligand interactions and predict the likelihood of a drug candidate binding to a target protein. The platform also incorporates computational biophysics, which uses physics-based simulations to predict protein-ligand complexes’ structural and dynamic properties.

One of the key advantages of Cyclica’s technology is its ability to analyze the entire proteome, rather than focusing on a limited number of targets. By analyzing the entire proteome, Cyclica can identify potential drug targets that may have been overlooked by traditional drug discovery methods. The company’s technology can also predict drug candidates’ potential side effects and toxicity, which can help identify safer and more effective drugs.

Cyclica’s Ligand Express platform has been used to identify potential drug candidates for various diseases, including cancer, neurodegenerative diseases, and infectious diseases. The company has also developed a drug repurposing platform, that uses AI to identify existing drugs that may have potential therapeutic uses for new indications. Drug repurposing can significantly reduce the time and cost of drug development, as existing drugs have already undergone clinical trials and have established safety profiles.

Cyclica has established partnerships with several leading pharmaceutical and biotech companies, including Bayer, Eli Lilly, and Merck. These partnerships have enabled Cyclica to apply its technology to real-world drug discovery projects and validate the efficacy and safety of its approach. The company has also received recognition for its innovative technology, including being named a “Global Cleantech 100” company by the Cleantech Group.

Cyclica’s team comprises experienced scientists, engineers, and business professionals with a deep understanding of AI, computational biophysics, and drug discovery. The company is led by CEO Naheed Kurji, who has over 20 years of experience in the biotech industry and has held leadership roles at several pharmaceutical companies. Kurji is supported by a team of experts in AI, machine learning, computational biophysics, and drug discovery, as well as a dedicated sales and marketing team.

“I believe that AI has the potential to transform drug discovery and improve global health by providing safer and more effective drugs in a more timely and cost-effective manner,” says Naheed Kurji, CEO of Cyclica. “At Cyclica, we are committed to advancing the field of AI-driven drug discovery and collaborating with leading pharmaceutical and biotech companies to develop innovative new drugs.” The company’s commitment to innovation, collaboration, and inclusivity has fostered a sense of community and belonging among its employees, leading to increased productivity, creativity, and innovation. Cyclica’s dedication to employee engagement and professional development has also contributed to its positive workplace culture and employee satisfaction. As the company continues to grow and evolve, it will undoubtedly maintain its commitment to its core values and continue to foster a culture of innovation, collaboration, and inclusivity.

Looking to the future, Cyclica is well-positioned to continue its growth and success in the biotechnology industry. The company has established partnerships with leading pharmaceutical and biotech companies, which have enabled Cyclica to apply its technology to real-world drug discovery projects and validate the efficacy and safety of its approach. As the field of AI-driven drug discovery continues to evolve, Cyclica is poised to remain at the forefront of innovation and collaboration, working to develop safer and more effective drugs in a more timely and cost-effective manner. With a dedicated team of experts in AI, machine learning, computational biophysics, and drug discovery, Cyclica is well-equipped to tackle some of the biggest challenges in drug development and improve global health for years to come.